Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
Harvard Business School
Mallinckrodt
Colorcon
Merck

Last Updated: November 28, 2022

Details for Patent: 6,428,810


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Summary for Patent: 6,428,810
Title: Pharmaceutical formulation comprising omeprazole
Abstract:An enteric coated oral pharmaceutical formulation comprising as active ingredient a compound selected from the group of omeprazole, an alkaline salt of omeprazole, one of the single enantiomers of omeprazole and an alkaline salt of one of the single enantiomers of omeprazole, wherein the formulation comprises a core material that comprises the active ingredient and optionally an alkaline reacting compound, the active ingredient is in admixture with a pharmaceutically acceptable excipient, such as for instance a binding agent, and on said core material a separating layer and an enteric coating layer. A hydroxypropyl cellulose (HPC) with a specific cloud point is used in the manufacture of the claimed pharmaceutical formulations. Furthermore, the application describes the processes for their preparation and the use of the claimed formulations in medicine.
Inventor(s): Bergstrand; Pontus (Gothenburg, SE), Wang; Peter (Molndal, SE)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:09/485,218
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,428,810
Patent Claim Types:
see list of patent claims
Formulation; Compound; Composition; Use; Process;

Drugs Protected by US Patent 6,428,810

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 6,428,810

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Sweden9803772Nov 05, 1998
PCT Information
PCT FiledNovember 03, 1999PCT Application Number:PCT/SE99/01989
PCT Publication Date:May 18, 2000PCT Publication Number: WO00/27366

International Family Members for US Patent 6,428,810

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 244002 See Plans and Pricing
Australia 1434600 See Plans and Pricing
Australia 774278 See Plans and Pricing
Brazil 9915087 See Plans and Pricing
Canada 2346988 See Plans and Pricing
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Dow
Baxter
Express Scripts
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.